Close Menu

This article has been updated from a previous version to clarify a statement about FDA-approved liquid biopsies.

NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that its PGDx Elio Plasma Resolve cell-free DNA assay has received a Breakthrough Device Designation from the Food and Drug Administration's Center for Device and Radiological Health.

PGDx's Elio assay uses next-generation sequencing to detect SNVs, amplifications, rearrangements, and microsatellite instability status to guide therapy selection for cancer patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.